SWARTZ CREEK, Mich., Sept 16 Diplomat Specialty Pharmacyannounced today that they have entered into a corporate agreement with EKRTherapeutics Inc. of Bedminster, NJ to offer co-payment assistance for ...
SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") has initiated the commercial ...
Jaguar planning to begin commercial launch of FDA-approved Gelclair ® prescription gel for oral mucositis (also called “chemo mouth”) in Q3 2024 Company to feature “Make Cancer Less Shitty” patient ...
MISSISSAUGA, Ontario, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the ...
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair ®, a protective gel for management of oral mucositis, a common, painful, and ...
The of Switzerland announced today that it has entered into an exclusive agreement with (Nasdaq: DARA) for U.S. commercial rights to Gelclair. Gelclair is an FDA-cleared product indicated for the ...
Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback